Dr. Janet Hoogstraate Joins AlzeCure Pharma as Newest Board Member

AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pioneering pharmaceutical company striving to innovate a robust portfolio of small molecule candidate drugs for the treatment of central nervous system diseases such as Alzheimer’s and pain, today announced the election of Janet Hoogstraate to its board of directors. This is a monumental step forward as AlzeCure pursues revolutionary treatments for debilitating conditions with the potential to transform the lives of millions worldwide.

Dr Janet Hoogstraate is a leading figure in life science, with extensive experience under her belt, including roles at Astra Zeneca. She holds a PhD in Biopharmaceutical Sciences from the University of Leiden in the Netherlands as well as an eMBA from Hult International Business School.

With great enthusiasm and knowledge surrounding neuroscience research, Janet has been an integral part of the Stockholm Brain Institute, and currently functions as the CEO of Valneva Sweden AB. With expertise in preclinical research, the pain area and biotech, she brings a wealth of understanding to AlzeCure.

“We are delighted to welcome Janet to our board, as she brings with her a vast wealth of knowledge in neuroscience and invaluable experience in developing preclinical research. Her addition to the board will further strengthen our company and its capabilities,” said AlzeCure’s Chairman Thomas Pollare.

I am delighted to be joining the board of AlzeCure Pharma, and I’m excited to contribute my expertise in neuroscience and regulatory registrations to the team of highly skilled and motivated individuals. This portfolio of projects in areas of great medical need is a fantastic opportunity to drive AlzeCure to greater success – and I’m ready and eager to make that happen.

About AlzeCure Pharma AB (publ)

AlzeCure® is a pioneering Swedish pharmaceutical company revolutionizing the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain.

With its stock listed on the Nasdaq First North Premier Growth Market, AlzeCure is developing an array of groundbreaking drug candidates based on three cutting-edge research platforms: NeuroRestore®, Alzstatin® and Painless, paving the way for unprecedented levels of care for people with long-term and debilitating illnesses.

NeuroRestore has revolutionized the medical world by introducing two innovative symptomatic drug candidates that work towards treating multiple ailments, including Alzheimer’s disease, traumatic brain injury, sleep apnea and Parkinson’s disease.

In addition, these groundbreaking drug candidates belong to the Alzstatin platform, which specializes in developing disease-modifying and preventive drugs for early stages of Alzheimer’s Disease.

For the realm of pain, Painless, another NeuroRestore research platform, has two projects: ACD440, currently in clinical development for the treatment of neuropathic pain, and TrkA-NAM for more severe pain in osteoarthritis.

To continue the pursuit of its own projects, NeuroRestore is expanding its boundaries through preclinical research, development, and clinical trials, as well as through business development to outlicense solutions to other pharma companies.

Leave a Comment